Introduction: In recent years, using radiation energies greater than 10 MV in patients with implantable cardioverter defibrillators (ICDs) has been contraindicated due to the risk of a power on reset (POR) occurring. The ICD is often greater than 30 cm from the treatment field and subject to scatter radiation only. The aim of this study was to use recent patient cases to verify published failure rates and treatment recommendations. Method: Five patients with ICDs who experienced a device malfunction during radiation therapy treatments were identified in three Sydney hospitals between 2008 and 2012. The types of treatments delivered during these events were assessed. Further assessment of all ICD patients at one Sydney hospital during this time was carried out to assess the rate of ICD failure during high energy treatments using 18 MV. Results: All ICDs that suffered malfunctions were exposed to scatter radiation only. All were exposed to partial or exclusive irradiation using 18 MV photons. Accumulated doses to the ICDs were estimated to be well below accepted dose limits found in literature. One centre reported a 22.2% rate of POR during exposure to 18 MV radiation therapy during this time frame. Conclusions: Where possible, radiation therapy using energies greater than 10 MV should be avoided for ICD patients. While the use of these energies carries a risk of failure, it must be weighed against potential benefit to the patient requiring treatment if no alternatives are available. Stringent monitoring of these patients, including regular cardiac device checks and ECG monitoring is recommended if treatment is to proceed with energies greater than 10 MV.
Introduction
Due to overlapping risk factors between cancer and cardiovascular disease, as well as an ageing population, the number of patients fitted with Implantable Cardioverter Defibrillators (ICD) requiring radiation therapy treatment in Australia is becoming more common. [1] [2] [3] There are a variety of protocols implemented in clinical centres worldwide, 4 to try to prevent device malfunction or failure identified as a power on reset (POR), where the device returns to a backup pacing mode. Pacing is generally returned to an inhibited pacing mode with antitachycardia (ATA) therapy switched on. Reprogramming is required to return to patient specific parameters.
There is a continual need to verify and update existing protocols with clinical evidence. Implantable Cardioverter Defibrillator PORs have been increasingly reported in the literature. Various case studies involving radiotherapy patients with ICDs have been published [5] [6] [7] [8] [9] since the introduction of the American Association of Physicists in Medicine pacemaker guidelines released in 1994, 10 with four studies reporting device failures. Thomas et al. 5 and Lau et al. 6 reported power-fraction of a radiation therapy treatment course 8 with an ICD that could not be reset and had to be explanted in emergency. Further large scale observational studies have continued to show POR occurring at energies 10 MV or greater, [11] [12] [13] [14] [15] [16] [17] [18] with Zaremba et al. 16 noting a fivefold increase in device malfunction when using energies greater than 15 MV. Dose recommendations for ICDs vary between the literature, with recommendations commonly suggesting 1 Gy, 16, 17, 19 but as high as 10 Gy. 20 This paper aims to assist in quantifying the risk of failure based on patient cases documented across three Australian radiation therapy centres.
Methods
Three hospitals within the Sydney metropolitan area with recorded incidents of ICD POR during radiation therapy were identified through conversations with department representatives at a NSW Cancer Institute EviQ meeting in 2010. Low and negligible risk research ethics approval was given by the appropriate institutional Human Resource Ethics Committee, with site specific approval given for data collection at the three hospital sites. Patients were included if they were identified as having incurred a POR during radiation therapy at the participating hospitals between 2008 and 2012 inclusive. A total of five patients were identified, as summarised in Table 1 . In one hospital, further ethics approval was sought to assess the treatments of all ICD patients during this time. As the patients identified only had treatments with either whole or partial use of 18 MV, only the ICD assessments of patients who received either whole or partial radiation therapy treatment using 18 MV were compared, and the rate of failure was quantified.
Results

Patient A
Patient A required treatment of prostatic carcinoma after a previous history of mitral valve repair and concomitant minor coronary artery bypass grafting requiring implantation of a cardiac resynchronisation defibrillator. A dose of 68 Gy in 35 fractions was prescribed to the prostate.
Thermoluminescent dosimeters (TLDs) were placed over the ICD site during the first treatment to estimate the dose to the ICD. A routine ICD check during treatment revealed the ICD had experienced multiple electrical resets during the course of treatment. Six single byte memory corruptions, where small amounts of data are either corrupted or lost as a result of radiation, electromagnetic interference (EMI) or physical damage were also identified, beginning from fraction one. The ICD was reprogrammed, and on advice from the manufacturers, the treatment was replanned to incorporate only 6 MV; the final two fractions were administered again using 18 MV. Treatment was completed with no further complications.
Patient B
Patient B presented for treatment to prostatic carcinoma with a dual chamber ICD inserted due to an abnormal cardiac rhythm. A dose of 74 Gy in 37 fractions was prescribed; no dose was estimated to the ICD. The day after treatment completion, the ICD was found to have incurred a partial reset, switching from dual mode pacing to ventricular only pacing, requiring device reprogramming. All other checks were within normal range and the patient was asymptomatic.
Patient C
Patient C presented with an ICD in situ, due to syncopal episodes and cardiac arrest, for treatment to a prostatic carcinoma. Seventy-four gray was planned to the prostate using high photon energy; no accumulated dose was estimated. ICD interrogation performed before initial treatment indicated no errors. The patient experienced symptoms around fraction twelve, with anorexia, nausea and abdominal discomfort, with unknown cause. At a routine ICD check 1 month post treatment, the ICD was unable to be interrogated. The patient was referred immediately to admission, however, declined as he had no current adverse symptoms. The device was explanted and sent to the manufacturer for analysis. The investigation summary stated that the ICD was subject to a hazard alert attributed to exposure to radiation, resulting from a parity error, where an irregular change in data 
Patient D
Patient D had a previous history of coronary artery disease with inducible tachycardia requiring a single chamber ICD insertion. The patient presented with a rectal carcinoma, and was treated to 25 Gy using a combination of 6 MV and 18 MV. The ICD received a total dose of 0.013 Gy during treatment, estimated by TLD measurements. After the initial treatment, a POR was found to have occurred during treatment. The device was reprogrammed and daily monitoring with ECG and daily cardiac device checks were performed for all remaining treatments. The ICD operated normally during fraction two, however, incurred another POR during the delivery of fraction three. The ICD was again reprogrammed and functioned normally for the remaining two fractions. Follow-up of the ICD has shown no further abnormalities.
Patient E
Patient E presented for management of a metastatic rectal carcinoma with an ICD implanted in the left upper chest for unknown reasons. The patient was treated using a mixture of 6 MV and 18 MV energies. A total dose of 0.023 Gy was estimated by TLDs to be received by the ICD. The ICD was checked before the first fraction, as well as at the beginning of fractions two, three and five. A POR occurred during the final fraction.
Treatments without incident
During this time, a further seven ICD patients were treated at the same centre as patients D and E, using conformal treatment techniques with either whole or partial use of 18 MV without incident. This equated to a 22.2% failure rate of ICDs during high energy photon treatments. Dose to the ICDs ranged from 0.013 Gy-~6.8 Gy, with no ICD exposed to direct radiation. In one case, a magnet was utilised during treatment without incident. These treatments are summarised in Table 2 . A further 16 patients were treated at this centre using 6 MV or electron energies, with one patient experiencing transient interference during treatment. No other failures were observed.
Discussion
Current published studies 11, 13, 20 have recommended that a photon beam energy greater than 10 MV should not be used in the treatment of ICD patients undergoing radiation therapy, with a maximum received cumulative dose to the ICD of less than 2 Gy throughout treatment. 21, 22 All ICDs that suffered a malfunction in this study were out of the direct radiation field at a distance greater than 30 cm from the nearest beam edge, and therefore were only exposed to scatter radiation. They were all treated with either partial or exclusive irradiation using 18 MV photons. Accumulated doses to the ICDs were estimated to be well below the limits commonly suggested in current literature. This study therefore supports current findings, that the scattered beam of high energy photons (>10 MV) has the potential to interfere with devices. Similar to recent findings by Zaremba et al. 16 . While all patients in our study received checks to their ICD at the conclusion of treatment, it is possible that any device malfunctions occurring in the days to weeks following treatment conclusion are not accounted for in this study. Long-term effects on the devices were not studied.
17,18
Treatment recommendations
Due to the risk of device failure, and potentially lethal complications associated with failure, the authors propose that it is not unreasonable to monitor these patients with the highest precautions achievable in a busy radiation oncology department. This is most important when disabling anti-tachycardia therapy (ATA) during treatment. Photon treatments utilising energies greater than 10 MV, those that induce neutron activation, should be avoided in patients with ICDs in favour of modern techniques incorporating intensity modulated beams where available. There are currently no known ways to limit the risk of using high energies. If neutron producing energies must be used, increased monitoring precautions should be employed, up to and including daily cardiac device checks, such as in patient D.
Doses up to 10 Gy are no longer considered a treatment limiting factor. 20, 23 Direct irradiation of the device is still contra-indicated due to the risk of interference and the device should be relocated away from the radiation beam. Appropriately trained personnel 20 should be present to ensure safe and effective treatment of patients with ICDs. The use of a magnet during each treatment to deactivate ATA therapy may be considered in consultation with the cardiologist to prevent inappropriate shocks being delivered to the patient. When a magnet is used, continuous monitoring via ECG and pulse oximetry must be utilised to ensure quick response to any patient deterioration during treatment. Cardiac resuscitation equipment should be available to treating staff at all times. Regular cardiac device checks are encouraged, up to once a week, due to the asymptomatic nature of these faults, with regular follow up to 6 months to detect any latent failure. In Australia, manufacturer cardiac technicians are available for cardiac device testing within the radiation oncology department upon request, and should be utilised. In international departments, the possibility of these resources being available should be researched and used, where available. If possible, audible alert tones should be switched on in the device to help physicians and patients identify hazard alerts within the devices and respond appropriately.
Indirect electron and orthovoltage therapy have not previously shown to have a detrimental effect on device function in the literature, however, given the serious risk of harm, further investigation is required to exclude or limit monitoring precautions for these patients.
In conclusion, radiation therapy may be used to treat patients with ICDs when departments utilise a comprehensive treatment protocol to manage the known risks of device malfunction. To minimise the risk of POR during radiation therapy in patients with ICDs, treatment using energies greater than 10 MV should be avoided in favour of newer techniques, especially in patients dependent on their device, where there is an absence of a perfusing rhythm without pacing. If an alternate treatment plan is not possible, the potential risk of failure should be communicated to the patient prior to treatment consent. Communication between Cardiology and Radiation Oncology departments should be encouraged to help better manage these patients. In addition, PORs that are identified by Cardiology after the patient has completed their radiation therapy treatment may not necessarily be communicated to the radiation oncology department, resulting in incidents being missed. Therefore, on a long-term basis, the follow-up of radiation therapy patients should be performed by both the cardiology and radiation therapy departments in co-operation. Records of these treatments should be entered into a national database to assist in further assessment of the risks posed to these patients. An observational case-control study is required to assess the frequency of failures during radiation therapy against a control population, to assess the adequacy of current treatment protocols. 
